Table 2. Bacteraemic relapse and outcome of 357 patients with methicillin-sensitive S. aureus bacteraemia (SAB) and a deep infection focus categorized according to adjunctive rifampicin therapy.

	Rifampicin therapy		Any length of rifampicin therapy vs. no rifampicin therapy
Variables	No therapy n = 96 (27%)	Therapy of any length n = 261 (73%)	OR (95% CI)	p- value
SAB relapse A	2 (2)	2 (<1)	0.40 (0.06–2.89)	0.349
Mortality, at 28 days	16 (17)	28 (11)	0.60 (0.31–1.17)	0.130
Mortality, at 60 days	22 (23)	35 (13)	0.51 (0.28–0.93)	0.027
Mortality, at 90 days	25 (26)	41 (16)	0.53 (0.30–0.93)	0.026

Patients with alcoholism, acute or chronic liver diseases, lack of deep infection foci, MRSA bacteraemia (n = 6) or a fatal outcome within 3 days have been excluded. Values are expressed as n (%).

^A SAB relapse within 90 days follow-up